Lysophosphatidic Acid Increases the Electrophysiological Instability of Adult Rabbit Ventricular Myocardium by Augmenting L-Type Calcium Current

Yong Wei1,2, Li-qun Zhao1, Bao-zhen Qi1, Xing Xiao3, Li He3, Gen-qing Zhou1, Song-wen Chen1, Hong-li Li1, Lei Ruan3, Cun-tai Zhang3, Shao-wen Liu1*

1 Department of Cardiology, Shanghai First People's Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China, 2 Department of Cardiology, Shanghai Songjiang Center Hospital, Shanghai, China, 3 Department of Geratology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China

Abstract

Lysophosphatidic acid (LPA) has diverse actions on the cardiovascular system and is widely reported to modulate multiple ion currents in some cell types. However, little is known about its electrophysiological effects on cardiac myocytes. This study investigated whether LPA has electrophysiological effects on isolated rabbit myocardial preparations. The results indicate that LPA prolongs action potential duration at 90% repolarization (APD90) in a concentration- and frequency-dependent manner in isolated rabbit ventricular myocytes. The application of extracellular LPA significantly increases the coefficient of APD90 variability. LPA increased L-type calcium current (I_{Ca,L}) density without altering its activation or deactivation properties. In contrast, LPA has no effect on two other ventricular repolarizing currents, the transient outward potassium current (I_{to}) and the delayed rectifier potassium current (I_{Kr}). In arterially perfused rabbit left ventricular wedge preparations, the monophasic action potential duration, QT interval, and Tpeak-end are prolonged by LPA. LPA treatment also significantly increases the incidence of ventricular tachycardia induced by S1/S2 stimulation. Notably, the effects of LPA on action potentials and I_{Ca,L} are PTX-sensitive, suggesting LPA action requires a G-protein-dependent manner.

Introduction

Lysophosphatidic acid (LPA) is an intermediate molecule produced during phospholipid metabolism. A water-soluble glycerol phospholipid with a simple structure, LPA is secreted from numerous cell types, such as platelets, fibroblasts, and ovarian cancer cells [1,2], and is present in very small amounts in human serum (with a concentration of 1–5 mM). It functions both as a component of the cell membrane and as an intracellular phospholipid signaling molecule [3] as an autocrine or paracrine mediator. Numerous and diverse biological processes are mediated by LPA, including cellular proliferation, cellular migration, differentiation, anti-apoptosis, actin cytoskeletal rearrangements, platelet aggregation, calcium mobilization, and neurotransmitter release [4]. LPA’s biological functions are mediated by at least six G-protein-coupled receptors (GPCRs) referred to as LPA1–6 [5–8], which are widely distributed in the brain, heart, kidney, spleen and other organs. These receptors couple to multiple G proteins, notably G_12/13, G_0, G_16, and possibly G_2, [5]. LPA activates multiple signaling cascades, including phosphoinositide 3-kinase, phospholipase C, mitogen-activated protein kinase, Rho family GTPase, and adenyl cyclase [9,10]. Interestingly, as one of its roles as an extracellular mediator, LPA has also been proposed to serve as an endogenous activator of the nuclear peroxisome proliferator activated receptor gamma (PPARγ) [11,12]. The assignment of specific biological functions to individual GPCR subtypes has been hampered by the overlapping expression of LPA receptors, their coupling to multiple G-proteins and their regulation of diverse signal transduction pathways. These characteristics result in pleiotropic responses in functional experiments, depending the cell type and the relative expression of LPA receptors [13].

LPA has important functions in the cardiovascular system, such as the induction of vascular smooth muscle contraction, the promotion of platelet aggregation, the stimulation of vascular smooth muscle cell and cardiac fibroblast proliferation, the promotion of cardiac hypertrophy, and the modulation of myocardial contractility [14]. Western blot and Northern blot analysis have indicated that the whole Endothelium Differentiation Gene (EDG)/LPA receptor family is expressed ubiquitously throughout the cardiovascular system. Thus, LPA may play a role in modulating cardiac function under physiological and/or pathological conditions. Accumulating evidence indicates that LPA plays an important role in regulating ion currents in multiple cell types [15–17]. However, the importance of LPA in regulating...
ion currents in myocardiocytes has not been studied. This work, using isolated myocardial preparations, examines the effects of LPA on action potential duration (APD) and membrane currents, and analyzes the possible underlying mechanisms. Overall, this study demonstrates that LPA is a key electrophysiological mediator in myocardiocytes.

Materials and Methods

Ethics Statement
All animal protocols in this study were approved by the Animal Care and Use Committee, Research Institute of Medicine, Shanghai Jiao Tong University, in accordance with National Institutes of Health guidelines and public law. All efforts were taken to minimize animal suffering.

Cell Preparations
Male adult New Zealand White rabbits (1.5 to 2.5 kg) were used. Single ventricular myocytes were dissociated enzymatically as previously described [18]. Briefly, rabbits were heparinized (200 U/kg IV) and anesthetized with sodium pentobarbital (50 mg/kg IV). Hearts were excised via thoracotomy, and the aortas were rapidly cannulated. Isolated hearts were mounted on a Langendorff apparatus and were retrogradely perfused through the aorta with Ca²⁺-free Tyrode’s solution (135 mM NaCl, 5.4 mM KCl, 1 mM MgSO₄, 0.33 mM NaH₂PO₄, 10 mM glucose, 10 mM HEPES, pH adjusted to 7.35 with NaOH) for 7 minutes. Samples were then treated with the same solution containing 0.5–0.8 mg/mL collagenase B (Worthington Chemical Co.) and 0.06 mg/mL protease XIV (Sigma Chemical Co.) for 15–20 minutes, followed by storage solution for 5 minutes, at a rate of 3–4 mL/min. The ventricle was then cut into small pieces, pipetted, and filtered through 200 µm nylon mesh. The isolated myocytes were stored in KB solution (50 mM L-glutamic acid, 3 mM MgCl₂, 20 mM taurine, 0.5 mM EGTA, 10 mM glucose, 10 mM HEPES, pH adjusted to 7.35 with KOH) at 4°C and were used for electrophysiological recordings 2–10 hours after isolation. Throughout the isolation procedure, all solutions were oxygenated with 100% O₂ and solution temperatures were maintained at 37°C.

Electrophysiological Recordings from Cell Preparations
A single-pipette whole-cell patch-clamp was applied to record action potentials and ion currents. The tip resistance of the glass pipette was 2.5 to 3.5 MΩ after being filled with an internal pipette solution. Action potentials were recorded in normal Tyrode’s solution (135 mM NaCl, 5.4 mM KCl, 1.8 mM CaCl₂, 1 mM MgCl₂, 0.33 mM NaH₂PO₄, 10 mM HEPES, 10 mM glucose, pH adjusted to 7.35 with NaOH). The pipette solution consisted of 120 mM KCl, 1 mM CaCl₂, 5 mM MgCl₂, 5 mM Na₃ATP, 11 mM EGTA, 11 mM glucose, and 10 mM HEPES (pH adjusted to 7.35 with KOH). Action potentials were elicited by application of a 15-ms depolarizing pulse through the pipette and were recorded at frequencies of 0.25 to 4 Hz. Action potential duration (APD) was measured at 90% and 50% of repolarization (APD₉₀ and APD₅₀). Ion currents were normalized to cell capacitance and expressed as current densities (pA/pF) to control cell size variability. For L-type calcium current (I_Ca,L) recordings, the bath solution was normal Tyrode’s solution and the pipette solution was 120 mM CsCl, 5 mM MgCl₂, 5 mM Na₃ATP, 11 mM EGTA, 11 mM glucose, and 10 mM HEPES (pH adjusted to 7.35 with CsOH). The cell membrane was clamped to a holding potential of −40 mV to inactivate Na⁺ and T-type calcium currents. I_Ca,L was elicited by a sequence of stimulation pulses. The standard voltage clamp protocol was a series of 300 ms voltage steps from −80 to +60 mV at a frequency of 0.25 Hz. The internal pipette solution for recording transient outward potassium current (I_K₁) and delayed rectifier potassium current (I_K₃) was composed of 60 mM KOH, 80 mM KCl, 40 mM aspartate, 5.0 mM HEPES, 10 mM EGTA, 5.0 mM MgATP, 5.0 mM sodium creatine phosphate, and 0.65 mM CaCl₂ (pH adjusted to 7.2 with NaOH). For I_K₆ recordings, the bath solution was normal Tyrode’s solution with nisoldipine (3 µM) added to block ICa,L. I_Ca,L was elicited from the holding potential of −80 mV with a subsequent 20-ms pre-pulse of −50 mV and by a series of 300 ms voltage steps from −90 to +50 mV at a frequency of 0.1 Hz. To measure I_K₆, cells were superfused with Tyrode’s solution mixed with CaCl₂ (100 µM), BaCl₂ (100 µM), tetrodotoxin (50 µM), and 4-aminopyridine (1 mM) to eliminate ICa,L, inward-rectifier potassium current (I_K₁), Na⁺ current and I_K₃, respectively. I_K₆ was elicited from the holding potential of −50 mV and by a series of 3000 ms voltage steps from −40 to +50 mV at a frequency of 0.1 Hz. Optimized compensation is essential for eliminating linear components from the current signal when investigating I_Ca,L and I_K₆. When recording action potential, I_K₆ and I_K₃ data were collected before and after 10-min perfusion with LPA in the same cell. When recording I_Ca,L, cells were randomly divided into two groups (group Control and group LPA) and only the initial recording data were collected. Voltage and current signals were filtered at 2 kHz and stored on a personal computer with PatchMaster software (EPC 10, HEKA Instruments) for analysis.

Arterially Perfused Rabbit Left Ventricular Wedge Preparations
The methodology for preparation of the arterially perfused ventricular wedge was similar to that previously described [19]. Briefly, 20 rabbits were anesthetized with sodium pentobarbital (50 mg/kg IV) and anticoagulated with heparin (200 U/kg IV). The heart was excised and submerged in cold (4°C) cardioplegic solution (109 mM NaCl, 24 mM KCl, 20 mM NaHCO₃, 0.9 mM NaH₂PO₄, 0.5 mM MgSO₄, 1.8 mM CaCl₂, 5.5 mM glucose, buffered with 95% O₂ and 5% CO₂, with pH adjusted to 7.35 with NaOH). The left circumflex branch of the coronary artery was cannulated and perfused with the same cardioplegic solution. Unperfused areas of the left ventricle were easily identified by their reddish appearance due to the presence of unflushed erythrocytes, and were removed. The cannulated preparation was then placed in a small heated tissue bath and arterially perfused with Tyrode’s solution (129 mM NaCl, 4 mM KCl, 0.9 mM NaH₂PO₄, 20 mM NaHCO₃, 1.8 mM CaCl₂, 0.5 mM MgSO₄, 5.5 mM glucose, buffered with 95% O₂ and 5% CO₂, and maintained at 35.7±0.2°C). The perfusate was delivered to the artery by constant flow with a roller pump. Perfusion pressure was monitored continuously with a pressure transducer and maintained at 35 to 45 mmHg.

Electrophysiological Recordings from the Wedge Preparations
The endocardial surface of the preparations was stimulated with bipolar silver electrodes, insulated except for the tips. A transmemural pseudo-electrocardiogram (ECC) of the wedge was recorded with a pair of silver/silver chloride electrodes positioned in the bath at opposite sites of the wedge and along the same vector as the transmembrane recordings. Monophasic action potentials were recorded from the endocardium using floating glass microelectrodes, with a resistance of 10–20 MΩ after being filled with...
potassium chloride solution (2.7 M). The impalement of microelectrodes was maintained approximately on the axis of the transmural ECG recording electrodes. Induced ventricular tachycardia (VT) was determined by pacing the apex endocardium of the arterially perfused ventricular wedge preparations with trains of eight conditioning current pulses (S1), delivered at predetermined rates (1.0 Hz), with each train being followed by a premature pulse (S2) of the same magnitude. The S1–S2 interval was progressively shortened in 10 ms steps. Induced VT was defined as over 3 continuous premature ventricular beats induced by S2.

Solution and Drug Preparation

The LPA (1-Oleoyl-sn-Glycero-3-Phosphate), protease XIV, MgATP, CsCl, CsOH, Na2ATP, tetrodotoxin, 4-aminopyridine and HEPES used in this study were obtained from Sigma Chemical Co. Collagenase B was purchased from Worthington Chemical Co. All other chemicals were obtained from China National Medicines Corporation Ltd. A stock solution (0.1 mg/mL) of LPA was prepared in calcium- and magnesium-free buffers and subsequently diluted in extracellular bath solution to the desired concentration.

Statistics

All continuous data are expressed as mean±SDM. Statistical significance was determined with the sample-paired Student’s t-test for paired observations: APD90, QT interval, Tpeak-end, and MAPD90 were recorded in conditions before and after LPA perfusion. Unpaired group comparisons of Ica,L (ex. groups without LPA vs groups with LPA) were made with the independent Student’s t-test. Two statistical approaches were used because the spontaneous rundown of Ica,L prevents recording paired observations before and after LPA perfusion. A two-way ANOVA test was performed to compare current densities as a function of both membrane potential and LPA treatment. Proportions of induced VT occurrences by S1S2 stimulation before and after LPA perfusion were compared using the Fisher exact test. Differences were considered significant at P<0.05.

Data for voltage-dependence of activation and inactivation of Ica,L were fitted to the Boltzmann equation: Y = 1/{1+exp[-(Vm-V1/2)/K]}, where Vm is the membrane potential, V1/2 is the half-activation or half-deactivation potential, and K is the inverse slope factor. For activation-Vm curves, Y represents the relative conductance (G/Gmax). For inactivation-Vm curves, Y represented the relative current (I/Imax).

Results

LPA Prolongs APD in Isolated Adult Rabbit Ventricular Myocytes

To test whether LPA mediates action potential duration (APD) in singly isolated adult rabbit ventricular myocardiocytes, APD before and after LPA treatment was examined. The data reveal that LPA prolongs APD in a concentration- and frequency-dependent manner (Fig. 1). ∆APD90 is the difference between APD recorded before and after LPA addition (∆APD90 = APD90 pre-LPA – APD90 post-LPA). Four LPA concentrations were tested: 1, 5, 10, and 20 μM. A dose of 1 μM did not alter APD90 at any frequency. A prolongation of APD appeared at 5 μM and had the greatest magnitude at 20 μM LPA. A mid-level concentration (10 μM) was selected for subsequent experiments.

Next, a time course of LPA’s effect on APD prolongation in rabbit ventricular myocytes at 1.0 Hz was performed (Fig. 2). APD gradually increased after LPA addition, with the prolongation of APD appearing at 2 min and peaking after 10 min of treatment. The prolonged APD induced by LPA was readily reversible after washing out. Therefore, we used a LPA treatment time of 10 minutes for subsequent experiments.

Treatment with LPA prolongs both APD90 and APD50 in ventricular myocytes at the frequency of 1 Hz. APD90 increased from 215.80±9.37 ms to 241.90±6.66 ms (P<0.01), while APD50 increased from 215.80±9.37 ms to 241.90±6.66 ms (P<0.01), while APD50.

Figure 1. Concentration and frequency-dependent prolongation of action potential duration (APD) induced by LPA in isolated rabbit ventricular myocytes. (A) Action potentials were recorded at different frequencies from 0.25 to 4.0 Hz before and after perfusion with various concentrations of LPA. Closed circles: 1 μM, open circles: 5 μM, closed triangles: 10 μM, open triangles: 20 μM. Delta APD90 is defined as the difference of APD90 recorded before and after LPA addition at a constant frequency (n = 10). (B) Representative traces of action potential recorded at the frequency of 1.0 Hz in cardiac myocytes without (Control) and with different concentrations of LPA (1, 5, 10, 20 μM).

doi:10.1371/journal.pone.0045862.g001
increased from 175.50 ± 4.43 ms to 200.60 ± 3.66 ms (P < 0.01). Notably, other action potential parameters, such as resting membrane potential (RMP), maximal rate of depolarization (Vmax), overshoot, and action potential amplitude (APA) did not change after LPA addition and washout (Table 1).

Beat-to-beat variation in APD exists in single ventricular myocytes paced at a constant rate [20]. It is an index positively associated with electrophysiological instability in myocardiocytes and contributes to arrhythmogenesis [21]. To examine APD90 variability, the coefficient of variability (CV) was calculated by dividing the standard deviation of 30 consecutive APD90 at 1.0 Hz by their mean (CV = SD/mean APD90 × 100%). The application of LPA increased the CV from 2.34% ± 0.31 to 4.68% ± 0.94 (n = 10, P < 0.01, Fig. 3A). These results demonstrate that LPA significantly increases APD90 variability. This change is also reflected in traces of representative action potentials recorded from 30 consecutive beats of one adult rabbit ventricular myocyte with and without LPA (Fig. 3B–C).

Effects of LPA on ICa,L in Isolated Adult Rabbit Ventricular Myocardiocytes

To determine whether ICa,L can explain APD prolongation, this current was examined. Voltage-clamp steps were applied for 300 ms from a holding potential of −40 mV to different depolarizing levels up to +60 mV at 0.25 Hz. Current-voltage (I–V) curves of the peak ICa,L densities indicate that ICa,L densities in myocytes with LPA treatment are higher than those in untreated myocytes from −20 mV to +30 mV (Fig. 4A). Representative traces of ICa,L in cardiac myocytes with (lower panel) and without (upper panel) LPA treatment are shown in Figure 4B.

To verify that LPA treatment increases ICa,L, the single-wave protocol was used to record single ICa,L traces at a holding potential of −40 mV and a test potential of 0 mV for 200 ms. LPA treatment significantly increased ICa,L density from −5.92 ± 0.68 pA/pF to −6.63 ± 0.61 pA/pF (n = 10, P < 0.05, Fig. 5A). Representative current traces of ICa,L in the absence (upper panel) and presence (lower panel) of LPA are shown in Fig. 5B. Though Gmax (LPA vs Control, 17.03 ± 1.91 vs 10.04 ± 3.57 pS, P < 0.05) was increased by LPA, it did not alter the activation curve of ICa,L (Fig. 5C), with no change in midpoint potential (V1/2) nor the slope factor (K) (Table 2). Inactivation properties were also unchanged with LPA treatment (Fig. 5D), with no change in V1/2 nor K (Table 2), regardless of an increased Imax (LPA vs Control, 6.74 ± 0.51 vs 5.92 ± 0.86 pA/pF, P < 0.05). The time course of the run-down of ICa,L was not altered by LPA either (Data were showed in Figure S1).

LPA has no Effect on Ito and IK Ventricular Repolarizing Currents

Three main ion currents, ICa,L, Ito, and IK, play a key role in ventricular repolarization. Although increased ICa,L could be a plausible explanation for APD prolongation, it was unclear...
whether LPA also had effects on other ventricular repolarizing currents, namely I_{to} and I_{K}. An examination of these currents indicates that LPA does not alter the I–V curves of neither I_{to} nor I_{K} (Fig. 6 and 7).

Impact of LPA on the Electrical Stability of Rabbit Left Ventricular Wedge Preparations

In order to confirm the electrophysiological effects of LPA on the myocardium, in vitro experiments were performed with arterially perfused rabbit left ventricular wedge preparations. After the addition of LPA (10 μM), monophasic action potential duration (MAPD_{90}) was prolonged from 215.01±4.85 ms to 238.64±7.46 ms (P<0.01, Fig. 8A). In addition, an increase of QT interval from 276.47±4.53 ms to 291.40±6.49 ms (P<0.01) occurred upon treatment (Fig. 8A). Tpeak-end is defined as the interval between the peak and the end of the T wave, and has been previously verified as a reliable measure of transmural dispersion of repolarization, which may reflect arrhythmic risk [22,23]. Tpeak-end increased with LPA treatment from 28.83±5.48 ms to 51.12±4.53 ms (P<0.01, Fig. 8A). In summary, MAPD, QT

Figure 3. LPA-induced increase in action potential duration (APD) variability in isolated rabbit ventricular myocytes. (A) Comparison of APD_{90} variability subsequently recorded at 1.0 Hz before and after LPA treatment (10 μM). *P<0.01 in paired t-test (n = 10). (B) Representative action potentials recorded from 30 consecutive beats in one adult rabbit ventricular myocyte without (upper panel) and with (lower panel) LPA treatment. Coefficient of APD_{90} variability = (SD/mean APD_{90})×100%.
doi:10.1371/journal.pone.0045862.g003

Figure 4. Effect of LPA on current-voltage relation of L-type calcium current (I_{Ca,L}) in isolated rabbit ventricular myocytes. (A) Current amplitudes corrected for cell size in the presence (open circles) and absence (solid circles) of LPA (10 μM) plotted against the test potentials. Error bars are SDM. *P<0.01, two-way ANOVA followed by the Bonferroni test, comparing peak current density of I_{Ca,L} at the same potential recorded in myocytes without LPA (n = 10). (B) Representative traces of I_{Ca,L} in cardiac myocytes without (upper panel) and with (lower panel) LPA.
doi:10.1371/journal.pone.0045862.g004
interval and Tpeak-end were all prolonged after LPA perfusion (Fig. 8C).

Further, the incidence of ventricular tachycardia (VT) induced by S1S2 stimulation was determined. Recordings were made in one of the ten myocytes before the addition of LPA and six of the ten myocytes following treatment. LPA significantly increased induced VT (Fig. 8B). Representative examples of VT induced by S1S2 stimulation and detected by simultaneously recording monophasic action potentials in the endocardium and the transmural ECG are shown in Fig. 8D.

PTX Abolishes LPA-induced Effects on Action Potentials and ICa_L

Previously, it has been observed that blocking G_i protein function with pertussis toxin (PTX) abolishes LPA-dependent modulation of myocardial contractility [3]. To test whether LPA’s effects on action potentials and ICa_L are dependent on G_i proteins, myocardiocytes were treated with PTX (Fig. 9). Compared to basal values, LPA treatment increases APD_90 by 12% (Fig. 9A), APD_50 by 15% (Fig. 9B), and ICa_L by 13% (Fig. 9C). Pretreatment of myocardiocytes with PTX (50 ng/mL) completely abolishes the
LPA-induced prolongation of APD<sub>90</sub> (Figure 9A) and APD<sub>50</sub> (Figure 9B) and increase in ICa,L (Figure 9C). PTX treatment alone did not alter basal values. These results indicate that the effects of LPA on action potentials and ICa,L are PTX-sensitive, demonstrating the involvement of G<sub>i</sub> protein in LPA signaling.

**Discussion**

Lysophosphatic acid (LPA) is an intermediate metabolite of phospholipid biosynthesis and functions as an intercellular lipid messenger [24]. Although LPA is widely reported to modulate multiple ion currents in some cell types, little was known about its electrophysiological effects on cardiac myocytes.

LPA has multiple activities in the cardiovascular system. It has been shown that LPA is involved in the processes of atherosclerosis and thrombogenesis [25,26]. LPA has also been found to regulate blood vessel tone [27], to have positive inotropic effects in the heart in rats [28], and to induce a hypertrophic response in cultured neonatal myocardiocytes through various signaling pathways [29–31]. However, prior to this study, there had been

**Figure 6.** LPA does not affect the current-voltage relation of transient outward potassium current (I<sub>to</sub>) in isolated rabbit ventricular myocytes. (A) Current amplitudes corrected for cell size observed in the presence (open circles) and in the absence (solid circles) of LPA were plotted against the test potentials. Error bars are SEM, n = 8. (B) Representative traces of I<sub>to</sub> in cardiac myocytes without (upper panel) and with (lower panel) LPA.

**Figure 7.** LPA does not affect the current-voltage relation of delayed rectifier potassium current (I<sub>K</sub>) in isolated rabbit ventricular myocytes. (A) Current amplitudes corrected for cell size observed in the presence (open circles) and in the absence (solid circles) of LPA plotted against the test potentials. No significant difference was observed, n = 7. (B) Representative traces of I<sub>K</sub> in cardiac myocytes without (upper panel) and with (lower panel) LPA treatment.
no investigation on the potential actions of LPA on electrophysiological regulation of ion currents and APD in cardiac myocytes. In other cell types, it has been verified that LPA is involved in numerous electrophysiological activities. For example, LPA opens a P-type Ca\(^{2+}\) channel in human erythrocytes [15]. Chang and colleagues also demonstrated that LPA increases intracellular Ca\(^{2+}\) through endogenous LPA receptors in C6 glioma and L2071 fibroblasts [32]. In vascular smooth muscle cells, LPA has been found to induce Ca\(^{2+}\) mobilization, which involves not only extracellular Ca\(^{2+}\) entry through the sarcolemma Na\(^+\)-Ca\(^{2+}\) exchanger, Na\(^+\)-H\(^+\) exchanger and store-operated Ca\(^{2+}\) channels, but also Ca\(^{2+}\) release from ryanodine-sensitive and InsP(3)-sensitive intracellular Ca\(^{2+}\) pools [33,34]. In addition, LPA has been shown to induce Cl\(^{-}\) current mobilization, which involves not only extracellular Ca\(^{2+}\) entry through the sarcolemma Na\(^+\)-Ca\(^{2+}\) exchanger, Na\(^+\)-H\(^+\) exchanger and store-operated Ca\(^{2+}\) channels, but also Ca\(^{2+}\) release from ryanodine-sensitive and InsP(3)-sensitive intracellular Ca\(^{2+}\) pools [33,34]. In addition, LPA has been shown to activate Cl\(^{-}\) current in cultured corneal keratocytes in a dose-dependent manner, which results in subsequent depolarization of the cells [16]. Furthermore, LPA can modulate potassium channels in neuronal cells [17,35]. Together, these observations suggest that LPA plays an important electrophysiological role in multiple cellular processes. It was reasonable to hypothesize, therefore, that LPA might also function in cardiac myocytes as a regulator of cardiac electrophysiological activity.

This study provides functional evidence that LPA is a modulator of cardiac electrophysiological stability. LPA prolongs APD and changes in electrophysiological properties that are conducive to arrhythmia. The increase of \(I_{\text{Ca,L}}\) densities is associated with prolonged APD at a physiological cycle length as well as prolongation of QT interval and Tpeak-end in ECG. Although low concentrations of LPA do not affect APD in isolated rabbit ventricular myocytes, high concentrations (5–20 \(\mu\)mol/L) produce a significant increase in the APD. LPA can thus be considered as an endogenous pro-arrhythmia factor if it reaches high levels in the plasma. This newly discovered action of LPA on the heart could be of pathophysiological importance in conditions like acute myocardial infarction, in which LPA is massively released by activated platelets.

Given the pronounced effects of LPA on APD prolongation, which ion channels are responsible for this action was an essential question to address. De Jong and colleagues have demonstrated that products secreted from activated human platelets induce changes in \(I_{\text{Ca,L}}\) and [Ca\(^{2+}\)]\(_i\), which result in action potential prolongation and the occurrence of EAD and DAD in rabbit myocytes [36]. Interestingly, although products of activated platelets consist of organic substrates and more than 2000 proteins, LPA is an important component [37]. \(I_{\text{Ca,L}}\) plays an important role in the plateau phase of the action potential and is one of the key ion currents determining APD. Experimental results indicate that LPA treatment increases the current density of \(I_{\text{Ca,L}}\). The increase of the inward \(I_{\text{Ca,L}}\) may therefore explain APD prolongation and variation. That LPA affects cellular electrophysiological properties, thereby modulating vulnerability to VT,
supports the idea that LPA exerts pro-arrhythmic effects. Our data are mainly consistent with the previous study of Xu et al [28], who found that LPA had the positive inotropic effect in rat heart and such action was abolished by the antagonist of L-type Ca\(^{2+}\) channel (Verapamil). They also demonstrated LPA (1–30 \(\mu\)M) failed to alter the basal intracellular concentration of free Ca\(^{2+}\) in freshly isolated rat myocardiocyte [28]. Nonetheless, our study indicates LPA is shown to increase IC\(_{a,L}\) in rabbit myocardiocytes, which may cause Ca\(^{2+}\) influx and increase [Ca\(^{2+}\)]\(_i\). The observed inability of LPA to increase [Ca\(^{2+}\)]\(_i\) in Xu’s study may be due to [Ca\(^{2+}\)]\(_i\) measurement in quiescent myocardiocytes only, without using electrically-stimulated myocardiocyte preparations.

LPA is reported to be present in serum at concentrations ranging from 1–5 \(\mu\)M under normal physiological conditions [38], and can reach up to 20 \(\mu\)mol/L in patients following acute myocardial infarction (AMI). During this condition, in response to injury and inflammation, LPA is massively released by thrombin-activated platelets [39]. Serum LPA levels can be increased more than two-fold 8 h after the onset of AMI, with maximum levels occurring at 48–72 h following onset. LPA concentration remains higher than basal levels 7 days after injury [40]. Based on these previous studies and the current work, LPA likely represents a crucial link between AMI and the development of malignant arrhythmia. After injury, the consequential impairments in repolarization may predispose the ischemic heart to lethal ventricular arrhythmias. Abnormally high levels of LPA, together with temporally and spatially selective expression of LPA receptor subtypes in disease conditions, may also account for the diverse bioactivities of LPA. This molecule may exert potentially deleterious electrophysiological effects on myocardiocytes under certain disease conditions, including not only AMI, but also heart failure and hypertrophic myopathy. Since LPA is released from activated platelets, it could be considered as a marker for predicting the incidence and severity of malignant arrhythmias after acute injury. LPA may be regarded as an endogenous pro-arrhythmic factor in some pathophysiological conditions. This work implies that inactive LPA analogues that compete for receptor binding may be an effective new approach to preventing arrhythmia.

Limitations of the present study include that isolated myocardiocytes may not represent the physiological response to LPA of in vivo myocardiocytes. In addition, the identification of individual figures and graphs in the text: Figure 9. The effects of LPA on action potentials and IC\(_{a,L}\) are abolished by pertussis toxin (PTX). LPA increases APD\(_{90}\) (A), APD\(_{50}\) (B) and IC\(_{a,L}\) (D) above basal values, which does not occur after PTX pretreatment, * \(P<0.05\), comparing the LPA treated sample with the control in the absence or presence of PTX, \(n=10\). IC\(_{a,L}\) was recorded with the single-wave protocol at a holding potential of −40 mV and a test potential of 0 mV for 200 ms. (C) LPA has no effect on APD\(_{20}\) without or with PTX pretreatment (\(n=10\)).

doi:10.1371/journal.pone.0045862.g009
LPA receptors that mediate specific ion currents is problematic for single myocytes, in which there may be multiple LPA receptor subtypes, with each receptor subtype potentially signaling via multiple G proteins. Several lines of evidence indicate that the effects of LPA on cardiac myocytes are mediated through receptors coupling to various G proteins, including Gi, Gq, and G12/13. However, specific antagonists for each LPA receptor subtype, which would allow the dissection of subtype-specific functions, are not currently available. For these reasons, this study could not identify the LPA receptor subtypes linked with the specific pathways underlying APD prolongation and the increase in ICa,L. Nevertheless, the effects of LPA on action potentials and ICa,L are PTX-sensitive, indicating the involvement of Gi proteins in LPA signaling. In the future, animals in which specific LPA receptors are knocked-out will be required to determine which LPA receptor subtypes are linked to modulation of particular ion channels in cardiac myocytes.

In summary, these results suggest that the LPA-mediated APD prolongation and increase of electrophysiological instability in adult rabbit ventricular myocardium are dependent on an increase in ICa,L. Importantly, this work provides evidence for a role of LPA in the process of arrhythmia, and implies that the blockade of LPA receptors could be a new approach for reducing the risk of ventricular arrhythmias under pathological conditions.

Supporting Information

Figure S1 The time course of the rundown of ICa,L in conditions without and with LPA bath. ICa,L was recorded by the single-wave protocol (at a holding potential of −40 mV and a test potential of 0 mV for 200 ms), n = 8. (TIFF)

Acknowledgments

The authors wish to thank Jiejuan Zheng, Dan Wang, Dan Rong, and Guang-wei Han for technical assistance with electrophysiological recordings.

Author Contributions

Conceived and designed the experiments: YW SWL CTZ. Performed the experiments: YW LQZ BZQ XX LH LR. Analyzed the data: YW SWC HLL. Wrote the paper: YW.

References

1. Pagis C, Simon MF, Valet P, Saulnier-Blache JS (2001) Lysophosphatidic acid synthesis and release. Prostaglandins Other Lipid Mediat 64: 1–10.
2. Rancoule C, Pradère JP, Gonzalez J, Klein J, Valet P, et al. (2011) Lysophosphatidic acid 1-receptor targeting agents for fibrosis. Expert Opin Investig Drugs 20: 657–667.
3. Tomar A, George SP, Mathew S, Khurana S (2009) Differential effects of lysophosphatidic acid and phosphatidylglycerol 4,5-biphosphate on actin dynamics by direct association with the actin-binding protein villin. J Biol Chem 284: 52199–52202.
4. Cremers B, Flesch M, Kostenis E, Maack C, Niedernberg A, et al. (2003) Modulation of myocardial contractility by lysophosphatidic acid (LPA). J Mol Cell Cardiol 35: 71–80.
5. Meyer zu Heringdorf D, Jakobs KH (2007) Lysophospholipid receptors: signalling, pharmacology and regulation by lysophospholipid metabolites. Biochim Biophys Acta 1768: 925–940.
6. Noguchi K, Ishii S, Shimizu T (2003) Identification of p2y9/GPR23 as a novel G protein-coupled receptor for lysophospholipid, structurally distant from the Edg family. J Biol Chem 278: 25600–25606.
7. Lee CW, Rivera R, Gardell S, Dubin AE, Chun J (2006) GPR92 as a new G12/13- and Gq-coupled lysophospholipid receptor that increases cAMP, LPA5. J Biol Chem 281: 23589–23597.
8. Tabata K, Baba K, Shiraiishi A, Ito M, Fujita N (2007) The orphan GPCR GPR87 was deorphanized and shown to be a lysophosphatidic acid receptor. Biochem Biophys Res Commun 363: 861–866.
9. Lin ME, Herr DR, Chun J (2010) Lysophosphatidic acid (LPA) receptors: signalling properties and disease relevance. Prostaglandins Other Lipid Mediat 91: 130–138.
10. Tigyi G, Parrill AL (2003) Molecular mechanisms of lysophosphatidic acid action. Prog Lipid Res 42: 480–526.
11. McIntyre TM, Ponnier AV, Silva AR, St Hilaire A, Xu Y, et al. (2003) Identification of an intracellular receptor for lysophosphatidic acid (LPA). LPA is a transcellular PPAR gamma agonist. Proc Natl Acad Sci USA 100: 131–136.
12. Tsukahara T, Tsukahara R, Yasuda S, Makarova N, Valentine WJ, et al. (2006) Different residues mediate recognition of 1-O-Octyllysophosphatidic acid and rosiglitazone in the ligand binding domain of peroxisome proliferator-activated receptor γ. J Biol Chem 281: 3398–3407.
13. Fukushima N, Chun J (2001) The LPA receptors. Prostaglandins Other Lipid Mediat 64: 21–32.
14. Smyth SS, Cheng HY, Miyasaka S, Panchatharam M, Morris AJ (2008) Roles of lysophosphatidic acid in cardiovascular physiology and disease. Biochim Biophys Acta 1786: 563–570.
15. Yang L, Andrews DA, Low PS (2000) Lysophosphatidic acid opens a Ca++ channel in human erythrocytes. Blood 95: 2420–2425.
16. Wang J, Carbone LD, Watsky MA (2002) Receptor-mediated activation of a CCl current by LPA and S1P in cultured cornual keratoocytes. Invest Ophthalmol Vis Sci 43: 3202–3208.
17. Cohen A, Sagon R, Somchek E, Segal-Hayoun Y, Zilberberg N (2009) Pain-associated signals, acidosis and lysophosphatidic acid, modulate the neuronal Kᵥ1.2 channel. Mol Cell Neurosci 40: 302–309.
18. Akita T, Jouyer RW, Lo C, Kumar R, Hartzell HC (1994) Developmental changes in modulation of calcium currents of rabbit ventricular cells by phosphodiesterase inhibitors. Circulation 90: 469–478.
19. Yan GX, Wu Y, Liu T, Wang J, Marinich RA, et al. (2001) Phase 2 early afterdepolarization as a trigger of polymorphic ventricular tachycardia in acquired long-QT syndrome: direct evidence from intracellular recordings in the intact left ventricular wall. Circulation 103: 2851–2856.
20. Zauli Mori, Pollard AE, Yang L, Spinetti KW (2000) Beat-to-beat repolarization variability in ventricular myocytes and its suppression by electrical coupling. Am J Physiol Heart Circ Physiol 278: H677–H687.
21. Hondeghem LM, Carlson I, Duker G (2001) Instability and triangulation of the action potential predict serious proarrhythmia, but action potential duration prolongation is antiarrhythmic. Circulation 103: 2004–2013.
22. Kaufman ES (2011) Arrhythmic risk in congenital long QT syndrome. J Electrocadio 44: 645–649.
23. Shimizu W, Horie M, Ohno S, Takemaka K, Yamaguchi M, et al. (2004) Mutation site-specific differences in arrhythmic risk and sensitivity to sympathetic stimulation in the LQT1 form of congenital long QT syndrome: multicenter study in Japan. J Am Coll Cardiol 44: 117–125.
24. Parrill AL, Sardar VM, Yuan H (2004) Sphingosine 1-phosphate and lysophosphatidic acid receptors: agonist and antagonist binding and progress toward development of receptor-specific ligands. Semin Cell Dev Biol 15: 467–476.
25. Spector AA (2003) Plaque rupture, lysophosphatidic acid, and thrombosis. Circulation 108: 641–643.
26. Karliner JS (2002) Lysophospholipids and the cardiovascular system. Biochim Biophys Acta 1582: 216–221.
27. Tokumura A, Yotsuomoto T, Masuda Y, Tanaka S (1995) Vasopressor effect of lysophosphatidic acid on spontaneously hypertensive rats and Wistar Kyoto rats. Res Commun Mol Pathol Pharmacol 90: 96–102.
28. Xu YJ, Radhi SS, Zhang M, Bhugra P, Dhallan NS (2002) Mechanism of the positive inotropic effect of lysophosphatidic acid in rat heart. J Cardiovasc Pharmacol Ther 7: 109–115.
29. Hila-Dandan R, Means CK, Gustafsson AB, Morissette MR, Adams JW, et al. (2004) Lysophosphatidic acid induces hypertrophy of neonatal cardiac myocytes via activation of Gi and Rho. J Mol Cell Cardiol 36: 481–493.
30. Wei L (2004) Lysophospholipid signaling in cardiac myocyte hypertrophy. J Mol Cell Cardiol 36: 465–468.
31. Chen J, Chen Y, Zhu W, Han Y, Han B, et al. (2008) Specific LPA receptor subtype mediates of LPA-induced hypertrophy of cardiac myocytes and involvement of Akt and NFκb signal pathways. J Cell Biochem 103: 1718–1731.
32. Chang YJ, Kim YL, Lee YK, Sacket SJ, Kim J, et al. (2007) Dioloyl phosphatidic acid increases intracellular Ca2+ through endogous LPA receptors in C6 glioma and L2071 fibroblasts. Prostaglandins Other Lipid Mediat 83: 268–276.
33. Xu YJ, Saini HK, Cheema SK, Dhallan NS (2005) Mechanisms of lysophosphatidic acid-induced increase in intracellular calcium in vascular smooth muscle cells. Cell Calcium 38: 569–579.
34. Ohata H, Yamada H, Momose K (2011) Lysophosphatidic acid induces shrun stress-dependent Ca2+ influx in mouse aortic endothelial cells in situ. Exp Physiol 96: 468–475.
35. Chemin J, Patel A, Duprat F, Zanouzi M, Lazardinski M, et al. (2005) Lysophosphatidic Acid-Operated K+ Channel. J Biol Chem 280: 4413–4421.
36. de Jong JS, Verkerk AO, van Borren MM, Zakhraeva-Zwiauer OM, Nieuwland R, et al. (2011) Activated human platelet products induce proarrhythmic effects in ventricular myocytes. J Mol Cell Cardiol 51: 347–356.
37. Coppinger JA, Cagney G, Toomey S, Kislinger T, Belton O, et al. (2004) Characterization of the proteins released from activated platelets leads to localization of novel platelet proteins in human atherosclerotic lesions. Blood 103: 2096–2104.
38. Moolenaar WH, van Meeteren LA, Giepmans BN (2004) The ins and outs of lysophosphatidic acid signaling. Bioessays 26: 870–881.
39. Swarthout JT, Walling HW (2000) Lysophosphatidic acid: receptors, signaling and survival. Cell Mol Life Sci 57: 1970–1983.
40. Chen X, Yang XY, Wang ND, Ding C, Yang YJ, et al. (2003) Serum lysophosphatidic acid concentrations measured by dot immunogold filtration assay in patients with acute myocardial infarction. Scand J Clin Lab Invest 63: 497–503.